TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8129213
Drug: Bitolterol mesylate
Normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bitolterol mesylate 0.5 to 3.5 mg by continuous-flow nebulization
Study: 2563320
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Terfenadine and Flurbiprofen
Study: 28000180
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (5-10 g gel/50-100 mg testosterone)
Study: 28000180
Drug: Placebo (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5-10 g gel)
Study: 17602078
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy in patients with p27Kip1-negative tumors
Study: 17602078
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy in patients with p27Kip1-positive tumors
Study: 17602078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cisplatin-based chemotherapy)
Study: 9420397
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for malignancies
Study: 8213706
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg po metoclopramide (single dose)
Study: 8213706
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg po quid for 7 days
Study: 29404806
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day; 3 weeks on/1 week off) plus Letrozole (2.5 mg/day; continuous)
Study: 28762932
Drug: Multivessel stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivessel stenting using 2nd generation drug covered stents
Study: 28762932
Drug: Staged revascularization
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staged revascularization using 2nd generation drug covered stents
Study: 22027932
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1% (Voltaren Ophthalmic)
Study: 22027932
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone sodium phosphate 0.1% (Sterodex)
Study: 14616980
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (525 IU daily for 3 months)
Study: 9582466
Drug: 5‐FU/adrenaline gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/adrenaline gel
Study: 9582466
Drug: 5‐FU/adrenaline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/adrenaline solution
Study: 9582466
Drug: 5‐FU gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU gel
Study: 8345231
Drug: Modified multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified multidrug therapy regimen (rifampicin 600 mg, clofazimine 100 mg, dapsone 100 mg daily for 21 days)
Study: 8345231
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO multidrug regimen (rifampicin 600 mg and clofazimine 300 mg monthly, dapsone 100 mg daily, clofazimine 100 mg on alternate days)
Study: 3578865
Drug: Tetracaine 0.5%/15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 0.5%/15 mg with 0.2 mg epinephrine
Study: 3578865
Drug: Bupivacaine 0.5%/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5%/20 mg without epinephrine
Study: 31504526
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (HD) Influenza Vaccine
Study: 31504526
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) Influenza Vaccine
Study: 22737871
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (intratyimpanic dexamethasone and basic drug group treatment)
Study: 22737871
Drug: Basic drug
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic drug group (ganglioside and vinpocetine injection)
Study: 19437180
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both programs
Study: 15790946
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate therapy (64 mmol/L per day, continuous intravenous dose, started within 4 days after SAH and continued until 14 days after occlusion of the aneurysm)
Study: 11451715
Drug: Reduced-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-fat spread enriched with plant sterol esters (1.1 g/d)
Study: 11451715
Drug: Reduced-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-fat spread enriched with plant sterol esters (2.2 g/d)
Study: 8297739
Drug: CEF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (cyclophosphamide 600 mg m-2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2)
Study: 7975663
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion at a dose of 12.63g in 300 ml of 0.9% NaCl over 90 min
Study: 378671
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily Sotalol (80 to 320mg/day)
Study: 378671
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily Sotalol (80 to 320mg/day)
Study: 26028098
Drug: 7-day levofloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day levofloxacin-dexlansoprazole based quadruple therapy
Study: 26028098
Drug: 14-day levofloxacin-dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day levofloxacin-dexlansoprazole based quadruple therapy
Study: 21955635
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium
Study: 11427642
Drug: Lisinopril (LIS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (LIS, n=35)
Study: 20201749
Drug: Lisinopril (LIS)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (LIS)
Study: 7750682
Drug: Ranitidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (600 mg/day)
Study: 7750682
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg/day)
Study: 3386845
Drug: Copolymer 1
Normalized name: glatiramer (copolymer 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer 1 (COP-1) - daily intramuscular doses of 20 mg (2 patients) and twice daily subcutaneous doses of 15 mg (3 patients)
Study: 31857264
Drug: NLP in
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP in combination with ICD-9-CM codes
Study: 24010917
Drug: 10-valent pneumococcal-Haemophilus
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Study: 24010917
Drug: Control meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meningococcal (ACYW135) conjugate vaccine
Study: 19798013
Drug: Posterior psoas
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior psoas compartment approach (N=18) using 30 mL of 1.5% mepivacaine
Study: 12923651
Drug: Tomato products
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato products (raw, sauce, and paste) providing approximately eight mg lycopene/day for three weeks (T21)
Study: 2623032
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral d-amphetamine in fasting state (FAST/DRUG)
Study: 2623032
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral d-amphetamine in fed state (FED/DRUG)
Study: 31056427
Drug: Low-dose CAL02
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CAL02 (4 mg/kg)
Study: 31056427
Drug: High-dose CAL02
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CAL02 (16 mg/kg)
Study: 21393255
Drug: L-BLP25 liposome
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BLP25 liposome vaccine (1000 μg subcutaneously)
Study: 21393255
Drug: Cyclophosphamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (300 mg/m2 i.v. single dose)
Study: 8418246
Drug: Intravenous diaziquone
Normalized name: Diaziquone
DrugBank: Diaziquone (DB17174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diaziquone (AZQ)
Study: 8418246
Drug: AZQ with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZQ with significant hematologic toxicity requiring dose reduction
Study: 25069621
Drug: Technology-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-based intervention (empirically supported behavior-change strategies, daily skills, self-monitoring text messages with personalized feedback, biweekly counseling calls from a health coach, access to a Facebook support group)
Study: 20210368
Drug: Rituximab (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (as a single agent or in combination with chemotherapy)
Study: 20210368
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to CHOP chemotherapy
Study: 20210368
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT)
Study: 12452245
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg before skin incision
Study: 12452245
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg after skin incision
Study: 12452245
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg and ketamine 30 mg before skin incision
Study: 12452245
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg and ketamine 30 mg after skin incision
Study: 10604407
Drug: Beta-carotene 60
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene 60 mg/d for 6 months, followed by randomization to continue beta-carotene or placebo for 12 additional months.
Study: 10604407
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after initial beta-carotene treatment.
Study: 10604407
Drug: Beta-carotene treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene treatment for 6 months.
Study: 10604407
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after beta-carotene treatment.
Study: 7864103
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administration (12.5-24 micrograms.kg-1.day-1; n = 8)
Study: 20687838
Drug: 3.75 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 dose)
Study: 20687838
Drug: 3.75 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (2 doses)
Study: 20687838
Drug: 3.75 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 or 2 doses)
Study: 18487212
Drug: Androgen priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen priming with anastrozole 1 mg on cycle days 2, 3, and 4, hCG 1250 IU, cetrorelix 3 mg on cycle day 2, rFSH 150 IU from cycle day 5
Study: 18487212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with flexible antagonist protocol
Study: 10228629
Drug: EMLA pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA pre-treatment
Study: 10228629
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo pre-treatment
Study: 8909454
Drug: Methazolamide (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (average dose 168 mg/day)
Study: 1985289
Drug: azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine (AZA) 3.0 mg/kg daily
Study: 6358645
Drug: Solcoseryl eye
Normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl eye gel
Study: 25675560
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at Neiguan (PC 6) and Jianshi (PC 5) combined with granisetron injection
Study: 19890207
Drug: Caffeinated soda
Normalized name: Magadi soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated soda (32 oz daily for 1 week)
Study: 19890207
Drug: Noncaffeinated soda
Normalized name: Magadi soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncaffeinated soda (32 oz daily for 1 week)
Study: 17302650
Drug: Collective exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collective exercise program (1 hour, twice weekly of walk, strength, balance, and flexibility training)
Study: 12478880
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (5 mg/16 hrs)
Study: 7665718
Drug: Quinine sulfate
Normalized name: Quinine Sulfate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulfate (200 to 300 mg every night)
Study: 31619325
Drug: Twice-daily BG
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily BG testing
Study: 31619325
Drug: 4-times-daily BG
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-times-daily BG testing
Study: 26358287
Drug: Resuspended NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuspended NPH insulin (R+)
Study: 26358287
Drug: Nonresuspended NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresuspended NPH insulin (R- horizontal)
Study: 26358287
Drug: Nonresuspended NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresuspended NPH insulin (R- up)
Study: 26358287
Drug: Nonresuspended NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonresuspended NPH insulin (R- down)
Study: 22257422
Drug: Inhaled N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled N-acetylcysteine (NAC) 352.4 mg by inhalation twice daily
Study: 22257422
Drug: Inhaled N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled N-acetylcysteine (NAC)
Study: 19463133
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium antagonists and ACE inhibitors
Study: 15359902
Drug: Timolol gel-forming
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol gel-forming solution (Tg)
Study: 7862918
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch delivering 0 mg per 24 h
Study: 7862918
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch delivering 22 mg per 24 h
Study: 7862918
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch delivering 44 mg per 24 h
Study: 79761
Drug: Control (non-absorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-absorbable antibiotics)
Study: 31742685
Drug: Modular cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular cognitive-behavioral therapy (CBT) consisting of 30 sessions targeting psychotic experiences and depression/anxiety
Study: 31742685
Drug: Modular cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular cognitive-behavioral therapy (CBT)
Study: 21426572
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with oral health education and supervised toothbrushing four times per year
Study: 17086470
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention (faxed physician reminders with osteoporosis treatment guidelines and patient counseling)
Study: 8424508
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion (10 micrograms/mL)
Study: 8424508
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) with morphine (1.0 mg/mL)
Study: 3621992
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate ointment applied once daily for 2 weeks
Study: 3621992
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of active treatment followed by 1 week of vehicle alone
Study: 30587217
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group psychotherapy ("Mind it!") in addition to existing treatment regime
Study: 10986782
Drug: Iron-fortified infant
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified infant cereal (10.2 mg iron) and pureed meat (0.75-1.7 mg iron) with whole cow milk for six months
Study: 30995645
Drug: 0.15% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine + 0.02 μg × kg‐1 × h‐1 DEX (group D1)
Study: 30995645
Drug: 0.15% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine + 0.05 μg × kg‐1 × h‐1 DEX (group D2)
Study: 29120262
Drug: Brimonidine Tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine Tartrate Ophthalmic Solution, 0.025%
Study: 27090436
Drug: Cholesterol treatment
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol treatment discussion
Study: 21849206
Drug: Prolonged anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged anticoagulation therapy suggested for patients with high FVIII and increased TG.
Study: 16249698
Drug: Probenecid (PBCD)
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probenecid (PBCD) and protease inhibitors (PIs)
Study: 12728198
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment administered by five psychiatrists on an outpatient basis for one year.
Study: 12728198
Drug: As-usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-usual treatment from primary care physicians.
Study: 12728198
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment elsewhere (not specified).
Study: 12728198
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (psychiatric treatment).
Study: 10591045
Drug: Topical acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acetylsalicylic acid
Study: 2128228
Drug: Phosphatidylserine (PS)
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (PS) 400 mg/daily
Study: 3158243
Drug: Tubocurarine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.05 mg/kg
Study: 906784
Drug: Gallamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.3 mg/kg
Study: 30488093
Drug: External Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Physical Vibration Lithecbole (EPVL) therapy
Study: 30488093
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPVL therapy)
Study: 28666965
Drug: Individualized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized antibiotic duration (discontinued 48 hours after clinical stability, with at least five days of total antibiotic treatment)
Study: 28666965
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic duration
Study: 28666965
Drug: Individualized antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized antibiotic duration
Study: 26003508
Drug: MDMA (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (25, 50, 100 mg)
Study: 26003508
Drug: Cannabis (THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (THC 300 µg/kg)
Study: 26003508
Drug: Cocaine (HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (HCl 300 mg)
Study: 23052987
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 mg or 70/50 mg loading dose on Day 1)
Study: 23052987
Drug: Micafungin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (150 mg)
Study: 21967254
Drug: Tacrolimus (n=11)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (n=11) with steroids for 5 days and azathioprine (1 mg/kg) if WBC ≥ 4000 cells/cm³